Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Amgen

Status and phase: Completed; Phase 1

Conditions: Tumors

Treatments: Drug: AMG 706; Drug: Anti-angiogenesis

Study type: Interventional

Funder types: Industry

Identifiers

NCT00093873

20030116

Details and patient eligibility

About

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

Enrollment: 71 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Exclusion Criteria:

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

71 participants in 1 patient group

AMG 706

Experimental group

Description:

AMG 706 QD

Treatment:

Drug: Anti-angiogenesis

Drug: AMG 706